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We read with interest the article by Villa and coworkers [1]
advocating the use of cystatin C as a measure of glomerular
filtration rate (GFR) in critically ill patients. However, we should
like to draw attention to several flaws in this study. First, Villa
and coworkers compared cystatin C with creatinine as a
measure of GFR, using body surface corrected creatinine
clearance as, what they call, a ‘gold standard’. However, in the
Discussion section of that report inulin and iothalamate
clearances are mentioned as gold standards, but they were
not used by these investigators. The use of body surface area
corrected creatinine clearance is questionable in both obese
and excessively lean individuals because the correlation
between surface area and lean body mass may be lost. Both
types of patients are frequently encountered in intensive care.
Second, Villa and coworkers employ a cutoff of 80 ml/min to
identify renal dysfunction, whereas a value of 50 ml/min is
generally accepted [2]. This could have a major influence on
the presented results. Third, patients with thyroid disorders or
on corticosteroid therapy were excluded. Almost all patients
with critical illness have low tri-iodothyronine values because
of changes in thyroid hormone metabolism (‘nonthyroidal
illness’), thus making recognition of thyroid disorders
problematic. Finally, we showed [3] that, in patients with
thyroid dysfunction, cystatin C is not a suitable measure of
GFR. In hypothyroidism creatinine levels are elevated but
cystatin C levels are low, whereas in hyperthyroidism
creatinine levels are low and cystatin C levels elevated.
Taken together, we disagree with the authors that cystatin C
could be used as a marker of GFR in intensive care patients.
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Authors’ response
P Villa, M Jiménez, M-C Soriano, J Manzanares and P Casasnovas
We read with interest the letter from Wulkan and coworkers
about the use of cystatine C as a marker of glomerular
filtration. The gold standard parameters for monitoring renal
function are clearances of exogenous substances (inulin,
[125]iothalamate, etc.), and in clinical practice the more
extensively used markers of glomerular function, despite their
limitations, are serum creatinine and creatinine clearance. In
our opinion creatinine clearance represents a reasonably
accurate and reliable estimate of GFR and is better than
serum creatinine, at least in critically ill patients. Therefore, we
compared serum cystatin C and serum creatinine with body
surface corrected creatinine clearance. Morbidly obese
patients were excluded from the study because of the
possible perturbation in the calculation of body surface
corrected creatinine clearance.
In their letter, Wulkan and coworkers comment on the fact
that we employed 80 ml/min per m2 creatinine clearance as
the cutoff point to identify renal dysfunction instead of the
more generally accepted 50 ml/min per m2. Although
50 ml/min per m2 is the more commonly used cutoff point,
other studies [4,5] used a cutoff point of 84 ml/min per m2.
We felt that it would be interesting to evaluate a more
sensitive marker of early renal dysfunction in critically ill
patients, and therefore we employed a cutoff point of
80 ml/min per m2 in our study.
In relation to the impact thyroid dysfunction has on serum
cystatin C, the study reported by Wulkan and coworkers [3]
was conducted in a hyperthyroid or hypothyroid population,
and so patients with known thyroid disease were excluded532
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from the study. ‘Nonthyroidal illness’ is common in critically ill
patients. This disorder typically presents with low free tri-
iodothyronine values, generally normal free tetra-
iodothyronine and normal thyroid-stimulating hormone, which
confounds extrapolation of published data in this population.
We feel that future studies to evaluate this issue are
warranted.
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